Top

Published in:

01-04-2020 | Urothelial Cancer | Original Article

Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder

Authors: Anjelica Hodgson, Achim A. Jungbluth, Nora Katabi, Bin Xu, Michelle R. Downes

Published in: Virchows Archiv | Issue 4/2020

Abstract

Immunotherapeutic strategies are increasingly used in the treatment of a number of malignancies including high-grade urothelial carcinoma (HGUC) of the bladder. Because of this, detailed and accurate assessment of the tumor immune microenvironment is paramount. In this study, we aimed to correlate the composition of the tumor immune microenvironment with oncologic outcome and the expression of two cancer testis antigens (CTAs), CT10 and PRAME, potential cancer vaccine targets, as well as major histocompatibility complex I (MHC I), a molecule associated with tumor immune escape and resistance to immunotherapy. Triplicate tissue microarrays (TMAs) were constructed using 207 cases of HGUC of the bladder. Oncologic outcome data was gathered for each case. Consecutive sections from the TMA blocks were stained with CD3, CD4, CD8, FOXP3, PD1, PD-L1, CT10, PRAME, and MHC I. Twenty-one percent and 15% of cases expressed CT10 and PRAME, respectively. Eighty-eight percent of cases showed absent or decreased MHC I expression. CT10-expressing tumors showed a significantly worse disease specific survival (p = 0.007, hazard ratio 2.245, confidence interval 1.223–4.122). CT10, PRAME, and MHC I expression significantly correlated with other some immune parameters. CT10 and PRAME are expressed in a subset of HGUC and CTA and MHC I expression correlate with a number of important immune parameters. Together, these findings highlight the potential for exploring novel immune therapeutic strategies in HGUC. Additional studies evaluating the clinical relevance of these findings are warranted.

Hodgson A, Liu SK, Vesprini D, Xu B, Downes MR (2018) Basal-subtype bladder tumours show a “hot” immunophenotype. Histopathology 73:748–757. https://doi.org/10.1111/his.13696 CrossRefPubMed

Hodgson A, Xu B, Satkunasivam R, Downes MR (2018) Tumour front inflammation and necrosis are independent prognostic predictors in high-grade urothelial carcinoma of the bladder. J Clin Pathol 71:154–160. https://doi.org/10.1136/jclinpath-2017-204562 CrossRefPubMed

Liu X, Dowell AC, Patel P, Viney RP, Foster MC, Porfiri E, James ND, Bryan RT (2014) Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette-Guérin. Future Oncol 10:1443–1456. https://doi.org/10.2217/fon.14.79 CrossRefPubMed

Zuiverloon TCM, Nieuweboer AJM, Vékony H, Kirkels WJ, Bangma CH, Zwarthoff EC (2012) Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 61:128–145. https://doi.org/10.1016/j.eururo.2011.09.026 CrossRefPubMed

Horn T, Laus J, Seitz AK, Maurer T, Schmid SC, Wolf P, Haller B, Winkler M, Retz M, Nawroth R, Gschwend JE, Kübler HR, Slotta-Huspenina J (2016) The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer. World J Urol 34:181–187. https://doi.org/10.1007/s00345-015-1615-3 CrossRefPubMed

Winerdal ME, Marits P, Winerdal M, Hasan M, Rosenblatt R, Tolf A, Selling K, Sherif A, Winqvist O (2011) FOXP3 and survival in urinary bladder cancer. BJU Int 108:1672–1678. https://doi.org/10.1111/j.1464-410X.2010.10020.x CrossRefPubMed

Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558–562. https://doi.org/10.1038/nature13904 CrossRefPubMed

Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:1909–1920. https://doi.org/10.1016/S0140-6736(16)00561-4 CrossRefPubMedPubMedCentral

Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JÁ, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD (2017) Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet 18:312–322. https://doi.org/10.1016/S1470-2045(17)30065-7 CrossRef

10.

Powles T, O’Donnell PH, Massard C et al (2017) Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol 3:e172411. https://doi.org/10.1001/jamaoncol.2017.2411 CrossRefPubMedPubMedCentral

11.

Donin NM, Lenis AT, Holden S, Drakaki A, Pantuck A, Belldegrun A, Chamie K (2017) Immunotherapy for the treatment of urothelial carcinoma. J Urol 197:14–22. https://doi.org/10.1016/j.juro.2016.02.3005 CrossRefPubMed

12.

Muthigi A, George AK, Brancato SJ, Agarwal PK (2016) Novel immunotherapeutic approaches to the treatment of urothelial carcinoma. Ther Adv Urol 8:203–214. https://doi.org/10.1177/1756287216628784 CrossRefPubMedPubMedCentral

13.

Guo C, Manjili MH, Subjeck JR et al (2013) Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res 119:421–475. https://doi.org/10.1016/B978-0-12-407190-2.00007-1 CrossRefPubMedPubMedCentral

14.

Wong KK, Li WA, Mooney DJ, Dranoff G (2016) Advances in therapeutic cancer vaccines. Adv Immunol 130:191–249. https://doi.org/10.1016/bs.ai.2015.12.001 CrossRefPubMed

15.

Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, Thatcher N, Wagstaff J, Zielinski C, Faulkner I, Mellstedt H (2014) Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol 11:509–524. https://doi.org/10.1038/nrclinonc.2014.111 CrossRefPubMed

16.

Boon T, Coulie PG, Van den Eynde B (1997) Tumor antigens recognized by T cells. Immunol Today 18:267–268. https://doi.org/10.1016/S0167-5699(97)80020-5 CrossRefPubMed

17.

Whitehurst AW (2014) Cause and consequence of cancer/testis antigen activation in cancer. Annu Rev Pharmacol Toxicol 54:251–272. https://doi.org/10.1146/annurev-pharmtox-011112-140326 CrossRefPubMed

18.

Gjerstorff MF, Andersen MH, Ditzel HJ (2015) Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget 6:15772–15787. https://doi.org/10.18632/oncotarget.4694 CrossRefPubMedPubMedCentral

19.

Yin B, Liu G, Wang X-S, Zhang H, Song YS, Wu B (2012) Expression profile of cancer-testis genes in transitional cell carcinoma of the bladder. Urol Oncol 30:886–892. https://doi.org/10.1016/j.urolonc.2010.08.017 CrossRefPubMed

20.

Sharma P, Gnjatic S, Jungbluth AA et al (2003) Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun 3:19CrossRefPubMed

21.

Lausenmeyer EM, Braun K, Breyer J, Gierth M, Denzinger S, Burger M, Voelker HU, Otto W (2018) Strong expression of cancertestis antigens CTAG1B and MAGEA3 is correlated with unfavourable histopathological features and MAGEA3 is associated with worse progression-free survival in urothelial bladder cancer. Urol Int 102:1–6. https://doi.org/10.1159/000493577 CrossRef

22.

Sharma P, Shen Y, Wen S, Bajorin DF, Reuter VE, Old LJ, Jungbluth AA (2006) Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 12:5442–5447. https://doi.org/10.1158/1078-0432.CCR-06-0527 CrossRefPubMed

23.

Epping MT, Wang L, Edel MJ, Carlée L, Hernandez M, Bernards R (2005) The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 122:835–847. https://doi.org/10.1016/j.cell.2005.07.003 CrossRefPubMed

24.

van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJM (2016) Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer 16:219–233. https://doi.org/10.1038/nrc.2016.16 CrossRefPubMed

25.

Tagliamonte M, Petrizzo A, Tornesello ML, Buonaguro FM, Buonaguro L (2014) Antigen-specific vaccines for cancer treatment. Hum Vaccines Immunother 10:3332–3346. https://doi.org/10.4161/21645515.2014.973317 CrossRef

26.

Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall T (2016) The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol 39:44–51. https://doi.org/10.1016/j.coi.2015.12.007 CrossRefPubMedPubMedCentral

27.

Hodgson A, Xu B, Downes MR (2017) p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant. Histopathology 71:296–304. https://doi.org/10.1111/his.13225 CrossRefPubMed

28.

Zhuang R, Zhu Y, Fang L et al (2006) Generation of monoclonal antibodies to cancer/testis (CT) antigen CT10/MAGE-C2. Cancer Immun 6:7PubMed

29.

Chevalier MF, Nardelli-Haefliger D, Domingos-Pereira S, Jichlinski P, Derré L (2014) Immunotherapeutic strategies for bladder cancer. Hum Vaccines Immunother 10:977–981. https://doi.org/10.4161/hv.27621 CrossRef

30.

Gupta M, Kates M, Bivalacqua TJ (2019) Immunotherapy in nonmuscle invasive bladder cancer: current and emerging treatments. Curr Opin Oncol 31:183–187. https://doi.org/10.1097/CCO.0000000000000533 CrossRefPubMed

31.

Dutcher GMA, Bilen MA (2018) Therapeutic vaccines for genitourinary malignancies. Vaccines 6:E55. https://doi.org/10.3390/vaccines6030055 CrossRefPubMed

32.

Jin S, Cao S, Li J, Meng Q, Wang C, Yao L, Lang Y, Cao J, Shen J, Pan B, Hu J, Yu Y (2018) Cancer/testis antigens (CTAs) expression in resected lung cancer. OncoTargets Ther 11:4491–4499. https://doi.org/10.2147/OTT.S159491 CrossRef

33.

Futawatari N, Fukuyama T, Yamamura R, Shida A, Takahashi Y, Nishi Y, Ichiki Y, Kobayashi N, Yamazaki H, Watanabe M (2017) Early gastric cancer frequently has high expression of KK-LC-1, a cancer-testis antigen. World J Gastroenterol 23:8200–8206. https://doi.org/10.3748/wjg.v23.i46.8200 CrossRefPubMedPubMedCentral

34.

Grah JJ, Katalinic D, Juretic A, Santek F, Samarzija M (2014) Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer. Tumori 100:60–68. https://doi.org/10.1700/1430.15817 CrossRefPubMed

35.

Yoshida N, Abe H, Ohkuri T et al (2006) Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int J Oncol 28:1089–1098PubMed

36.

Matković B, Juretić A, Spagnoli GC, Šeparović V, Gamulin M, Šeparović R, Šarić N, Bašić-Koretić M, Novosel I, Krušlin B (2011) Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: retrospective immunohistochemical study. Croat Med J 52:171–177CrossRefPubMedPubMedCentral

37.

Chitale DA, Jungbluth AA, Marshall DS, Leitao MM, Hedvat CV, Kolb D, Spagnoli GC, Iversen K, Soslow RA (2005) Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray. Mod Pathol Off J U S Can Acad Pathol Inc 18:119–126. https://doi.org/10.1038/modpathol.3800232 CrossRef

38.

Prasad ML, Jungbluth AA, Patel SG, Iversen K, Hoshaw-Woodard S, Busam KJ (2004) Expression and significance of cancer testis antigens in primary mucosal melanoma of the head and neck. Head Neck 26:1053–1057. https://doi.org/10.1002/hed.20112 CrossRefPubMed

39.

Bandić D, Juretić A, Sarcević B et al (2006) Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study. Croat Med J 47:32–41PubMedPubMedCentral

40.

Zhang Y, Zhang Y, Zhang L (2019) Expression of cancer-testis antigens in esophageal cancer and their progress in immunotherapy. J Cancer Res Clin Oncol 145:281–291. https://doi.org/10.1007/s00432-019-02840-3 CrossRefPubMedPubMedCentral

41.

Nishiyama T, Tachibana M, Horiguchi Y et al (2001) Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin Cancer Res 7:23–31PubMed

42.

Obara W, Ohsawa R, Kanehira M, Takata R, Tsunoda T, Yoshida K, Takeda K, Katagiri T, Nakamura Y, Fujioka T (2012) Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer. Jpn J Clin Oncol 42:591–600. https://doi.org/10.1093/jjco/hys069 CrossRefPubMed

43.

Colombel M, Heidenreich A, Martínez-Piñeiro L, Babjuk M, Korneyev I, Surcel C, Yakovlev P, Colombo R, Radziszewski P, Witjes F, Schipper R, Mulders P, Witjes WPJ (2014) Perioperative chemotherapy in muscle-invasive bladder cancer: overview and the unmet clinical need for alternative adjuvant therapy as studied in the MAGNOLIA trial. Eur Urol 65:509–511. https://doi.org/10.1016/j.eururo.2013.10.056 CrossRefPubMed

44.

Sabbatino F, Schwab JH, Ferrone S, Ferrone CR (2013) Evolution of studies of HLA class I antigen processing machinery (APM) components in malignant cells. Clin Transpl 453–463

45.

Garrido F, Ruiz-Cabello F, Aptsiauri N (2017) Rejection versus escape: the tumor MHC dilemma. Cancer Immunol Immunother 66:259–271. https://doi.org/10.1007/s00262-016-1947-x CrossRefPubMed

Title: Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder
Authors: Anjelica Hodgson
Achim A. Jungbluth
Nora Katabi
Bin Xu
Michelle R. Downes
Publication date: 01-04-2020
Publisher: Springer Berlin Heidelberg
Keywords: Urothelial Cancer
Urothelial Cancer
Published in: Virchows Archiv / Issue 4/2020
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-019-02661-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2020

The evolving spectrum of endocervical adenocarcinoma in situ (AIS)

Tumor budding as a prognostic factor in pancreatic ductal adenocarcinoma

Methodological approach to microscopic colitis diagnosis: reply

The clinical, morphological, and genetic heterogeneity of endometrial stromal sarcoma

The leading role of pathology in assessing the somatic molecular alterations of cancer: Position Paper of the European Society of Pathology

Clinicopathologic features of Buschke-Löwenstein tumor: a multi-institutional analysis of 38 cases